PDCD1 and metastatic melanoma: To the best of our knowledge, this is the first report describing first-line use of a PD-1 inhibitor in a renal transplant patient for the management of BRAF wild-type metastatic melanoma without prior immunotherapy, targeted therapy, or chemotherapy.